|
|
|
02.04.26 - 13:33
|
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives (GlobeNewswire EN)
|
|
|
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide....
|
|
|
01.04.26 - 20:46
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 01.04.2026 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 01.04.2026
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 01.04.2026
ISIN Name
US3906071093 GREAT LA.DR.+DO.NEW DL-01
US68278B1070 ONESTR.INC.CL.A DL-,0001
US72941H5090 PLUS THERAPEUTICS
US9114601035 UTD SECURITY BANCSHARES
USU02400AB28 AMC NETWORKS 24/29 REGS
XS2901882618 LEVERAGE SHARES 3MSTR ETP...
|
|
|
01.04.26 - 17:09
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
US72941H5090 Plus Therapeutics Inc. 01.04.2026 US72941H8060 Plus Therapeutics Inc. 02.04.2026 Tausch 25:1
XS2901882618 Leverage Shares PLC 01.04.2026 XS3304269429 Leverage Shares PLC 02.04.2026 Tausch 143:1...
|
|
|
|
|
|
|
31.03.26 - 13:33
|
Plus Therapeutics Announces Reverse Stock Split (GlobeNewswire EN)
|
|
|
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 2, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on April 2, 2026 under the Company's existing trading symbol, “PSTV.” At such time, the Company's common stock will also commence trading with a new CUSIP number, 72941H806....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.01.26 - 14:03
|
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering (GlobeNewswire EN)
|
|
|
HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $0.38 per share and will expire five years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 5,921,052 shares of common stock and/or war...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
